ASH 2018 | PD-1 blockade as salvage following anti-BCMA CAR-T in R/R myeloma

Adam Cohen

PD-1 checkpoint inhibitor combination regimens are being investigated as a salvage therapy for relapsed/refractory multiple myeloma patients who progress after anti-BCMA CAR T-cell therapy, as discussed here by Adam Cohen, MD, of the University of Pennsylvania, Philadelphia, PA. Dr Cohen highlights the results; that this combination can induce re-expansion of the CAR T-cells, although this effect was transient and infrequent. This indicates that certain patients may respond to this strategy or other immune-modulating approaches. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video